Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.
South Korean cancer vaccine maker KAEL-GemVax has appointed CPA Global as its IP management specialist.
Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.
The High Court in Australia has said for the first time that a method of medical treatment for the human body can be a patentable invention.
Takeda has announced that Christophe Weber, a member of GlaxoSmithKline’s global corporate executive team, will be joining the company as chief operating officer by April next year.
The US government has said it is now advocating a “differential” approach to policies on patenting drugs as part of continuing trade negotiations with Pacific countries.
A Japanese research institution has collaborated with three Indian organisations to launch two new virtual centres for scientists and students.
The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.